Dendritic Cell Therapy
Personalized immunotherapies based on dendritic cells — CytoCare provides the starting material for innovative treatment approaches.
The Foundation
What are dendritic cells?
Dendritic cells are the most important antigen-presenting cells of the immune system. They serve as the bridge between innate and adaptive immunity.
In immunotherapy, monocytes are obtained from the blood and differentiated ex vivo into dendritic cells. These are loaded with tumor-specific antigens and returned to the patient to trigger a targeted immune response against cancer cells. This approach is being researched and increasingly used clinically for various solid tumors and hematological diseases.
Our Role
How CytoCare provides the starting material
The quality of dendritic cell therapy depends critically on the quality of the monocytes. CytoCare supplies leukapheresis products with high monocyte content as the optimal starting basis.
- Leukapheresis with targeted enrichment of monocytes
- High cell viability through gentle collection procedures
- Fresh or cryopreserved delivery as required
- GMP-compliant processes for clinical programs
- Close coordination with the treating center